Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Cytotherapy. 2010 Oct;12(6):807–817. doi: 10.3109/14653249.2010.491821

Figure 8.

Figure 8

p38MAPK inhibition does not affect survival or teratoma formation in vivo. (A–D) Sections of mouse hearts injected with SB203580-treated hESC-derived hCM were stained with anti-GFP antibody to detect retention of viable hCM 60 days after injection. Sections were counterstained with DAPI (blue) to detect nuclei. (A, B) and (C, D) are from two representative hearts (n = 5). Clusters of GFP-expressing hESC-derived hCM (brown) were detected (arrows) in all injected hearts. Bar 100 μm (A,C); 50 μm (B,D). (E, F) Sections of mouse heart injected with SB203580-treated hESC-derived hCM were stained with H&E to survey for teratoma tissue. “(E, F) 4X and 20X magnification of injection site (lower right) in representative heart. There was no evidence of teratoma formation in any of the injected hearts (n = 5). Bar 100 μm.